Replimune to Present at Two Upcoming Investor Conferences

Rhea-AI Summary

Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company focused on developing novel oncolytic immunotherapies, has announced its participation in two upcoming investor conferences. The company's management team will be presenting and hosting investor meetings at these events:

1. BMO 2024 Oncology Summit on Tuesday, October 8, 2024

2. 3rd Annual Roth Healthcare Opportunities Conference on Wednesday, October 9, 2024

These conferences provide Replimune with an opportunity to showcase its progress in the field of oncolytic immunotherapies and engage with investors. The company's presence at these events underscores its commitment to advancing its clinical-stage pipeline and maintaining open communication with the investment community.

WOBURN, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that members from the Replimune management team will present and host investor meetings at the following two conferences:

BMO 2024 Oncology Summit
Date: Tuesday, October 8, 2024

3^rd Annual Roth Healthcare Opportunities Conference
Date: Wednesday, October 9, 2024

About Replimune 
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.

Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com

Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com

FAQ

Which investor conferences will Replimune (REPL) attend in October 2024?

Replimune (REPL) will attend the BMO 2024 Oncology Summit on October 8, 2024, and the 3rd Annual Roth Healthcare Opportunities Conference on October 9, 2024.

What is Replimune's (REPL) focus as a biotechnology company?

Replimune (REPL) is a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies.

When is Replimune (REPL) scheduled to present at the BMO 2024 Oncology Summit?

Replimune (REPL) is scheduled to present at the BMO 2024 Oncology Summit on Tuesday, October 8, 2024.

What activities will Replimune (REPL) engage in at the upcoming investor conferences?

Replimune's (REPL) management team will present and host investor meetings at both the BMO 2024 Oncology Summit and the 3rd Annual Roth Healthcare Opportunities Conference.

On which stock exchange is Replimune (REPL) listed?

Replimune (REPL) is listed on the Nasdaq stock exchange.